Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Porcine insulin is a biologic drug derived from the pancreas of pigs. It is a protein hormone composed of alpha and beta chains processed from pro-insulin and forms a hexameric structure. Porcine insulin closely resembles human insulin in structure and function, differing by only one amino acid. Its primary mechanism of action is to facilitate the uptake of glucose into cells by binding to the human insulin receptor, thereby lowering blood glucose levels. It is used as replacement therapy for patients with diabetes mellitus who require exogenous (injected) insulin due to insufficient endogenous production. Porcine insulins are available in various formulations (short-acting, intermediate-acting, mixed) and have historically been important for people with allergies or sensitivities to recombinant human insulins[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on porcine insulin.